Literature DB >> 20452317

Integrin alpha 6 regulates glioblastoma stem cells.

Justin D Lathia1, Joseph Gallagher, John M Heddleston, Jialiang Wang, Christine E Eyler, Jennifer Macswords, Qiulian Wu, Amit Vasanji, Roger E McLendon, Anita B Hjelmeland, Jeremy N Rich.   

Abstract

Cancer stem cells (CSCs) are a subpopulation of tumor cells suggested to be critical for tumor maintenance, metastasis, and therapeutic resistance. Prospective identification and targeting of CSCs are therefore priorities for the development of novel therapeutic paradigms. Although CSC enrichment has been achieved with cell surface proteins including CD133 (Prominin-1), the roles of current CSC markers in tumor maintenance remain unclear. We examined the glioblastoma stem cell (GSC) perivascular microenvironment in patient specimens to identify enrichment markers with a functional significance and identified integrin alpha6 as a candidate. Integrin alpha6 is coexpressed with conventional GSC markers and enriches for GSCs. Targeting integrin alpha6 in GSCs inhibits self-renewal, proliferation, and tumor formation capacity. Our results provide evidence that GSCs express high levels of integrin alpha6, which can serve not only as an enrichment marker but also as a promising antiglioblastoma therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452317      PMCID: PMC2884275          DOI: 10.1016/j.stem.2010.02.018

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  59 in total

1.  Patterns of laminins and integrins in the embryonic ventricular zone of the CNS.

Authors:  Justin D Lathia; Bruce Patton; D Mark Eckley; Tim Magnus; Mohamed R Mughal; Takako Sasaki; Maeve A Caldwell; Mahendra S Rao; Mark P Mattson; Charles ffrench-Constant
Journal:  J Comp Neurol       Date:  2007-12-20       Impact factor: 3.215

2.  Targeting cancer stem cells through L1CAM suppresses glioma growth.

Authors:  Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.

Authors:  Kyeung Min Joo; Shi Yean Kim; Xun Jin; Sang Yong Song; Doo-Sik Kong; Jung-Ii Lee; Ji Won Jeon; Mi Hyun Kim; Bong Gu Kang; Yong Jung; Juyoun Jin; Seung-Chyul Hong; Woong-Yang Park; Dong-Sup Lee; Hyunggee Kim; Do-Hyun Nam
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

4.  Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.

Authors:  Alfred T Ogden; Allen E Waziri; Richard A Lochhead; David Fusco; Kim Lopez; Jason A Ellis; Joann Kang; Marcela Assanah; Guy M McKhann; Michael B Sisti; Paul C McCormick; Peter Canoll; Jeffrey N Bruce
Journal:  Neurosurgery       Date:  2008-02       Impact factor: 4.654

5.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

6.  Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions.

Authors:  Qin Shen; Yue Wang; Erzsebet Kokovay; Gang Lin; Shu-Mien Chuang; Susan K Goderie; Badrinath Roysam; Sally Temple
Journal:  Cell Stem Cell       Date:  2008-09-11       Impact factor: 24.633

Review 7.  The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.

Authors:  Scott Bidlingmaier; Xiaodong Zhu; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2008-06-06       Impact factor: 4.599

8.  Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma.

Authors:  Qin Shu; Kwong Kwok Wong; Jack M Su; Adekunle M Adesina; Li Tian Yu; Yvonne T M Tsang; Barbara C Antalffy; Patricia Baxter; Laszlo Perlaky; Jianhua Yang; Robert C Dauser; Murali Chintagumpala; Susan M Blaney; Ching C Lau; Xiao-Nan Li
Journal:  Stem Cells       Date:  2008-04-10       Impact factor: 6.277

9.  Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma.

Authors:  Eli E Bar; Aneeka Chaudhry; Alex Lin; Xing Fan; Karisa Schreck; William Matsui; Sara Piccirillo; Angelo L Vescovi; Francesco DiMeco; Alessandro Olivi; Charles G Eberhart
Journal:  Stem Cells       Date:  2007-07-12       Impact factor: 6.277

10.  Laminin enhances the growth of human neural stem cells in defined culture media.

Authors:  Peter E Hall; Justin D Lathia; Maeve A Caldwell; Charles Ffrench-Constant
Journal:  BMC Neurosci       Date:  2008-07-23       Impact factor: 3.288

View more
  296 in total

1.  CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Authors:  Noriyuki Kijima; Naoki Hosen; Naoki Kagawa; Naoya Hashimoto; Akiko Nakano; Yasunori Fujimoto; Manabu Kinoshita; Haruo Sugiyama; Toshiki Yoshimine
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

Review 2.  Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells.

Authors:  Xiao-hong Yao; Ying Liu; Keqiang Chen; Wanghua Gong; Ming-yong Liu; Xiu-wu Bian; Ji Ming Wang
Journal:  Int Immunopharmacol       Date:  2011-09-17       Impact factor: 4.932

3.  Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.

Authors:  J M Heddleston; Q Wu; M Rivera; S Minhas; J D Lathia; A E Sloan; O Iliopoulos; A B Hjelmeland; J N Rich
Journal:  Cell Death Differ       Date:  2011-08-12       Impact factor: 15.828

4.  Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling.

Authors:  Hira Lal Goel; Bryan Pursell; Clive Standley; Kevin Fogarty; Arthur M Mercurio
Journal:  J Cell Sci       Date:  2012-02-02       Impact factor: 5.285

5.  α6-Integrin is required for the adhesion and vasculogenic potential of hemangioma stem cells.

Authors:  David M Smadja; Coralie L Guerin; Elisa Boscolo; Ivan Bieche; John B Mulliken; Joyce Bischoff
Journal:  Stem Cells       Date:  2014-03       Impact factor: 6.277

6.  Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Authors:  Amy Haseley; Sean Boone; Jeffrey Wojton; Lianbo Yu; Ji Young Yoo; Jianhua Yu; Kazuhiko Kurozumi; Joseph C Glorioso; Michael A Caligiuri; Balveen Kaur
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

Review 7.  Cancer stem cells: a new framework for the design of tumor therapies.

Authors:  Boyan K Garvalov; Till Acker
Journal:  J Mol Med (Berl)       Date:  2010-10-02       Impact factor: 4.599

8.  AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.

Authors:  Petreena S Campbell; Nicole Mavingire; Salma Khan; Leah K Rowland; Jonathan V Wooten; Anna Opoku-Agyeman; Ashley Guevara; Ubaldo Soto; Fiorella Cavalli; Andrea Irene Loaiza-Pérez; Gayathri Nagaraj; Laura J Denham; Olayemi Adeoye; Brittany D Jenkins; Melissa B Davis; Rachel Schiff; Eileen J Brantley
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

9.  Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.

Authors:  Kang Ho Kim; Ho Jun Seol; Eun Hee Kim; Jinguen Rheey; Hyun Jin Jin; Yeri Lee; Kyeung Min Joo; Jeongwu Lee; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

10.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.